.png)
Reddress
Point-of-care autologous whole-blood-clot dressing for hard-to-heal wounds (ActiGraft)
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
RedDress is pursuing a focused medtech growth strategy centered on autologous, point-of-care wound care, with commercialization anchored by FDA/CE-cleared products and distributor/GPO expansion in the U.S. and international markets.[2][7][8][10] Its trajectory suggests a company moving from clinical validation into broader market penetration, supported by meaningful funding and a growing commercial footprint.[3][8][10]
Efficiency Ratio
The company appears relatively efficient in converting a small-to-mid-size organization into regulatory, funding, and distribution outcomes, but operational scale remains modest versus its global market ambitions.[4][13][14]
Evidence Signals
Raised $26 million in a Series D round, bringing total disclosed funding to $43 million.
ActiGraft Pro was selected by Healogics Wound Care Supply for addition to its iSupply GPO.
Entered a contract with Capstone Health Alliance to expand access to ActiGraft across a large hospital purchasing network.
Legacy Medical Consultants acquired the right to exclusively market ActiGraft Pro across U.S. care settings, including hospitals, VA, DoD, and outpatient wound-care centers.
ActiGraft is FDA-cleared and CE-marked for wound care use.
Company reports over 6,000 to almost 7,000 patients treated across the U.S. and 30+ other countries since clearance.
LinkedIn lists the company as privately held with 11-50 employees and 4,031 followers.
- About
- Israeli advanced-wound-care company (Israel-based, with US subsidiary RedDress Inc. in Ponte Vedra Beach/Jacksonville, FL), founded in 2009 by Dr. Igal Kushnir (MD) and Alon Kushnir (CEO). Its ActiGraft / ActiGraft PRO systems create an autologous whole-blood clot at the point of care — mixing a small sample of the patient's own whole blood with a proprietary coagulation powder to form, in under five minutes, an in-vitro blood-clot tissue applied topically as a biologic scaffold and protective covering to restart the natural healing cascade. FDA 510(k)-cleared and CE-marked (2020), with US Medicare (G-code) reimbursement and a Vizient GPO contract; used in 6,000+ patients across 30 countries. Primarily for chronic/hard-to-heal wounds (diabetic, venous, pressure ulcers) but also cleared for traumatic, post-surgical and debrided wounds. Combat relevance is moderate/secondary — applicable to prolonged field care and complex/burn wound management, not acute hemorrhage control.
- Tags
- #woundcare #autologous #wholeblood #clot #chronicwounds #dfu #pointofcare #fda #regenerative